Balchem (BCPC) Q4 2024 earnings summary

Executive summary

• Achieved record full-year sales of $954 million (up 3.4% YoY) and Q4 sales of $240 million (up 4.9% YoY), led by Human Nutrition & Health and Specialty Products.

• Delivered record Q4 adjusted EBITDA of $62.8 million (up 13.4%) and full-year adjusted EBITDA of $250.3 million (up 8.4%).

• Adjusted net earnings for Q4 were $36.9 million (up 19.3%), and full-year adjusted net earnings were $143 million (up 10.2%).

• Continued innovation with multiple new product launches and exceeded 2030 GHG emissions reduction goal with a 32% reduction in Scope 1 and 2 emissions.

• Robust free cash flow supported dividend increases and significant debt reduction.

Financial highlights

• Q4 gross margin was $86.3 million (36% of sales, up 320 bps YoY); full-year gross margin was $336.2 million.

• Q4 net income was $34 million (up 26%), with Q4 GAAP EPS of $1.03 and adjusted EPS of $1.13; full-year GAAP EPS was $3.93, adjusted EPS $4.37.

• Free cash flow for the year was $147.2 million; Q4 cash flow from operations was $52 million.

• Net debt reduced to $140 million, with a leverage ratio of 0.5x–0.6x.

• Dividend per share increased 10% to $0.87, marking 16 consecutive years of double-digit growth.

Outlook and guidance

• Expecting continued top and bottom-line growth in 2025, with strong momentum in all segments and a focus on innovation and geographic expansion.

• Human Nutrition & Health segment anticipated to maintain strong performance, with nutrients business expected to outpace food ingredients.

• Animal Nutrition & Health segment projected to see ongoing growth in ruminant business, while monogastric remains flat until European market recovers.

• Specialty Products expected to deliver year-over-year growth again in 2025.

• Margin profile expected to remain healthy, with potential risks from tariffs and input cost inflation.